Page last updated: 2024-10-26

disulfiram and Astrocytoma, Grade IV

disulfiram has been researched along with Astrocytoma, Grade IV in 29 studies

Research Excerpts

ExcerptRelevanceReference
"To evaluate the efficacy and safety of disulfiram and copper as add-on to alkylating chemotherapy in patients with recurrent glioblastoma."9.69Effect of Disulfiram and Copper Plus Chemotherapy vs Chemotherapy Alone on Survival in Patients With Recurrent Glioblastoma: A Randomized Clinical Trial. ( Bartek, J; Carstam, L; Gulati, S; Hylin, S; Jakola, AS; Kinhult, S; Lindskog, M; Löfgren, D; Magelssen, H; Mudaisi, M; Rashid, HB; Salvesen, Ø; Solheim, O; Solheim, TS; Strandéus, M; Werlenius, K, 2023)
"Preclinical studies have suggested promising activity for the combination of disulfiram and copper (DSF/Cu) against glioblastoma (GBM) including re-sensitization to temozolomide (TMZ)."9.30A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma. ( Boockvar, J; Campian, JL; Chaudhary, R; Chinnaiyan, P; Cohen, AL; Fink, K; Goldlust, S; Huang, J; Marcus, S; Wan, L, 2019)
"Disulfiram has shown promising activity including proteasome inhibitory properties and synergy with temozolomide in preclinical glioblastoma (GBM) models."9.27Final results of a phase I dose-escalation, dose-expansion study of adding disulfiram with or without copper to adjuvant temozolomide for newly diagnosed glioblastoma. ( Ansstas, G; Campian, JL; DeWees, TA; Gujar, AD; Huang, J; Kim, AH; Lockhart, AC; Tran, DD; Tsien, C, 2018)
"Disulfiram, a generic alcohol aversion drug, has promising preclinical activity against glioblastoma (GBM)."9.22A phase I study to repurpose disulfiram in combination with temozolomide to treat newly diagnosed glioblastoma after chemoradiotherapy. ( Campian, JL; DeWees, TA; Gujar, AD; Huang, J; Kim, AH; Lockhart, AC; Tran, DD; Tsien, CI, 2016)
"Mesenchymal glioblastoma stem cells (GSCs), a subpopulation in glioblastoma that are responsible for therapy resistance and tumor spreading in the brain, reportedly upregulate aldehyde dehydrogenase isoform-1A3 (ALDH1A3) which can be inhibited by disulfiram (DSF), an FDA-approved drug formerly prescribed in alcohol use disorder."8.02Repurposing Disulfiram for Targeting of Glioblastoma Stem Cells: An In Vitro Study. ( Eckert, F; Ganser, K; Handgretinger, R; Huber, SM; Klumpp, L; Prause, L; Schleicher, S; Stransky, N; Zips, D; Zirjacks, L, 2021)
" Development strategies using molecular encapsulation of DS and the parenteral dosage forms improve the anticancer pharmacology of the drug."7.01Clinical, pharmacological, and formulation evaluation of disulfiram in the treatment of glioblastoma - a systematic literature review. ( Benkő, BM; Lamprou, DA; Sebe, I; Sebestyén, A; Zelkó, R, 2023)
"Hypoxia is one of the determinants of GSC."5.72PLGA-Nano-Encapsulated Disulfiram Inhibits Hypoxia-Induced NF-κB, Cancer Stem Cells, and Targets Glioblastoma In Vitro and In Vivo. ( Armesilla, AL; Azar, K; Bian, XW; Kannappan, V; Kilari, RS; Kurusamy, S; Liu, P; Liu, Y; Morris, MR; Najlah, M; Wang, W; Wang, Z, 2022)
"To evaluate the efficacy and safety of disulfiram and copper as add-on to alkylating chemotherapy in patients with recurrent glioblastoma."5.69Effect of Disulfiram and Copper Plus Chemotherapy vs Chemotherapy Alone on Survival in Patients With Recurrent Glioblastoma: A Randomized Clinical Trial. ( Bartek, J; Carstam, L; Gulati, S; Hylin, S; Jakola, AS; Kinhult, S; Lindskog, M; Löfgren, D; Magelssen, H; Mudaisi, M; Rashid, HB; Salvesen, Ø; Solheim, O; Solheim, TS; Strandéus, M; Werlenius, K, 2023)
"Disulfiram (DSF) is an anti-alcoholism drug which functions by inhibiting ALDHs."5.62Disulfiram Sensitizes a Therapeutic-Resistant Glioblastoma to the TGF-β Receptor Inhibitor. ( Gean, PW; Lin, MX; Liu, CC; Sze, CI; Wu, CL, 2021)
"Disulfiram (DSF) has shown its effectiveness against GBM, especially with copper ion (Cu)."5.62Nose-to-brain delivery of disulfiram nanoemulsion in situ gel formulation for glioblastoma targeting therapy. ( Iqbal, S; Li, A; Li, C; Ma, D; Ma, L; Ma, W; Qu, Y; Sun, X; Xu, Z; Zhao, Z; Zheng, D, 2021)
"Glioblastoma is one of the most lethal cancers in humans, and with existing therapy, survival remains at 14."5.43Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma. ( Aman, A; Cairncross, JG; Dang, NH; Datti, A; Easaw, JC; Grinshtein, N; Hao, X; Kaplan, DR; King, JC; Luchman, A; Lun, X; Robbins, SM; Senger, DL; Uehling, D; Wang, X; Weiss, S; Wells, JC; Wrana, JL, 2016)
"These brain tumors are often resistant to chemotherapies like temozolomide (TMZ) and there are very few treatment options available to patients."5.38Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma and over-rides resistance to temozolomide. ( Berns, R; Dunn, SE; Fotovati, A; Hu, K; Kast, RE; Kong, E; Lee, C; Luk, M; Pambid, M; Toyota, B; Toyota, E; Triscott, J; Yip, S, 2012)
"Preclinical studies have suggested promising activity for the combination of disulfiram and copper (DSF/Cu) against glioblastoma (GBM) including re-sensitization to temozolomide (TMZ)."5.30A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma. ( Boockvar, J; Campian, JL; Chaudhary, R; Chinnaiyan, P; Cohen, AL; Fink, K; Goldlust, S; Huang, J; Marcus, S; Wan, L, 2019)
"Disulfiram has shown promising activity including proteasome inhibitory properties and synergy with temozolomide in preclinical glioblastoma (GBM) models."5.27Final results of a phase I dose-escalation, dose-expansion study of adding disulfiram with or without copper to adjuvant temozolomide for newly diagnosed glioblastoma. ( Ansstas, G; Campian, JL; DeWees, TA; Gujar, AD; Huang, J; Kim, AH; Lockhart, AC; Tran, DD; Tsien, C, 2018)
"Disulfiram, a generic alcohol aversion drug, has promising preclinical activity against glioblastoma (GBM)."5.22A phase I study to repurpose disulfiram in combination with temozolomide to treat newly diagnosed glioblastoma after chemoradiotherapy. ( Campian, JL; DeWees, TA; Gujar, AD; Huang, J; Kim, AH; Lockhart, AC; Tran, DD; Tsien, CI, 2016)
"Mesenchymal glioblastoma stem cells (GSCs), a subpopulation in glioblastoma that are responsible for therapy resistance and tumor spreading in the brain, reportedly upregulate aldehyde dehydrogenase isoform-1A3 (ALDH1A3) which can be inhibited by disulfiram (DSF), an FDA-approved drug formerly prescribed in alcohol use disorder."4.02Repurposing Disulfiram for Targeting of Glioblastoma Stem Cells: An In Vitro Study. ( Eckert, F; Ganser, K; Handgretinger, R; Huber, SM; Klumpp, L; Prause, L; Schleicher, S; Stransky, N; Zips, D; Zirjacks, L, 2021)
"Constructed from a theoretical framework, the coordinated undermining of survival paths in glioblastoma (GBM) is a combination of nine drugs approved for non-oncological indications (CUSP9; aprepitant, auranofin, captopril, celecoxib, disulfiram, itraconazole, minocycline, quetiapine, and sertraline) combined with temozolomide (TMZ)."3.91The efficacy of a coordinated pharmacological blockade in glioblastoma stem cells with nine repurposed drugs using the CUSP9 strategy. ( Grieg, Z; Langmoen, IA; Sandberg, CJ; Skaga, E; Skaga, IØ; Vik-Mo, EO, 2019)
" Development strategies using molecular encapsulation of DS and the parenteral dosage forms improve the anticancer pharmacology of the drug."3.01Clinical, pharmacological, and formulation evaluation of disulfiram in the treatment of glioblastoma - a systematic literature review. ( Benkő, BM; Lamprou, DA; Sebe, I; Sebestyén, A; Zelkó, R, 2023)
"Among the different types of brain tumors, glioblastoma (GBM) is considered the most aggressive and remains extremely difficult to treat."2.52Concise review: bullseye: targeting cancer stem cells to improve the treatment of gliomas by repurposing disulfiram. ( Dunn, SE; Rose Pambid, M; Triscott, J, 2015)
"Hypoxia is one of the determinants of GSC."1.72PLGA-Nano-Encapsulated Disulfiram Inhibits Hypoxia-Induced NF-κB, Cancer Stem Cells, and Targets Glioblastoma In Vitro and In Vivo. ( Armesilla, AL; Azar, K; Bian, XW; Kannappan, V; Kilari, RS; Kurusamy, S; Liu, P; Liu, Y; Morris, MR; Najlah, M; Wang, W; Wang, Z, 2022)
"Disulfiram (DSF) is an anti-alcoholism drug which functions by inhibiting ALDHs."1.62Disulfiram Sensitizes a Therapeutic-Resistant Glioblastoma to the TGF-β Receptor Inhibitor. ( Gean, PW; Lin, MX; Liu, CC; Sze, CI; Wu, CL, 2021)
"Disulfiram (DSF) has shown its effectiveness against GBM, especially with copper ion (Cu)."1.62Nose-to-brain delivery of disulfiram nanoemulsion in situ gel formulation for glioblastoma targeting therapy. ( Iqbal, S; Li, A; Li, C; Ma, D; Ma, L; Ma, W; Qu, Y; Sun, X; Xu, Z; Zhao, Z; Zheng, D, 2021)
"Glioblastoma is one of the most lethal cancers in humans, and with existing therapy, survival remains at 14."1.43Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma. ( Aman, A; Cairncross, JG; Dang, NH; Datti, A; Easaw, JC; Grinshtein, N; Hao, X; Kaplan, DR; King, JC; Luchman, A; Lun, X; Robbins, SM; Senger, DL; Uehling, D; Wang, X; Weiss, S; Wells, JC; Wrana, JL, 2016)
"These brain tumors are often resistant to chemotherapies like temozolomide (TMZ) and there are very few treatment options available to patients."1.38Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma and over-rides resistance to temozolomide. ( Berns, R; Dunn, SE; Fotovati, A; Hu, K; Kast, RE; Kong, E; Lee, C; Luk, M; Pambid, M; Toyota, B; Toyota, E; Triscott, J; Yip, S, 2012)

Research

Studies (29)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (3.45)29.6817
2010's22 (75.86)24.3611
2020's6 (20.69)2.80

Authors

AuthorsStudies
Fernandes, GFDS1
Fernandes, BC1
Valente, V1
Dos Santos, JL1
Liu, CC1
Wu, CL1
Lin, MX1
Sze, CI1
Gean, PW1
Zirjacks, L1
Stransky, N1
Klumpp, L1
Prause, L1
Eckert, F1
Zips, D1
Schleicher, S1
Handgretinger, R1
Huber, SM1
Ganser, K1
Kannappan, V3
Liu, Y1
Wang, Z1
Azar, K1
Kurusamy, S1
Kilari, RS1
Armesilla, AL3
Morris, MR1
Najlah, M1
Liu, P3
Bian, XW1
Wang, W7
Benkő, BM1
Lamprou, DA1
Sebestyén, A1
Zelkó, R1
Sebe, I1
Werlenius, K1
Kinhult, S1
Solheim, TS1
Magelssen, H1
Löfgren, D1
Mudaisi, M1
Hylin, S1
Bartek, J2
Strandéus, M1
Lindskog, M1
Rashid, HB1
Carstam, L1
Gulati, S1
Solheim, O1
Salvesen, Ø1
Jakola, AS1
Qu, Y1
Li, A1
Ma, L1
Iqbal, S1
Sun, X1
Ma, W1
Li, C1
Zheng, D1
Xu, Z1
Zhao, Z1
Ma, D1
Huang, J3
Campian, JL3
Gujar, AD2
Tsien, C1
Ansstas, G1
Tran, DD2
DeWees, TA2
Lockhart, AC2
Kim, AH2
Mettang, M1
Meyer-Pannwitt, V1
Karpel-Massler, G4
Zhou, S2
Carragher, NO2
Föhr, KJ1
Baumann, B2
Nonnenmacher, L2
Enzenmüller, S1
Dahlhaus, M1
Siegelin, MD1
Stroh, S1
Mertens, D1
Fischer-Posovszky, P1
Schneider, EM1
Halatsch, ME5
Debatin, KM2
Westhoff, MA2
Koh, HK1
Seo, SY1
Kim, JH1
Kim, HJ1
Chie, EK1
Kim, SK1
Kim, IH1
Chaudhary, R1
Cohen, AL1
Fink, K1
Goldlust, S1
Boockvar, J1
Chinnaiyan, P1
Wan, L1
Marcus, S1
Skaga, E1
Skaga, IØ1
Grieg, Z1
Sandberg, CJ1
Langmoen, IA1
Vik-Mo, EO1
Darling, JL3
Kast, RE6
Boockvar, JA1
Brüning, A1
Cappello, F1
Chang, WW1
Cvek, B2
Dou, QP1
Duenas-Gonzalez, A1
Efferth, T1
Focosi, D1
Ghaffari, SH1
Ketola, K1
Khoshnevisan, A1
Keizman, D1
Magné, N1
Marosi, C1
McDonald, K1
Muñoz, M1
Paranjpe, A1
Pourgholami, MH1
Sardi, I1
Sella, A1
Srivenugopal, KS1
Tuccori, M1
Wirtz, CR2
Jennewein, C1
Schneider, M1
Krause, A1
Simmet, T1
Bachem, MG1
Zembko, I1
Ahmed, I1
Farooq, A1
Dail, J1
Tawari, P2
Mcconville, C2
Triscott, J2
Rose Pambid, M1
Dunn, SE2
Tsien, CI1
Lun, X1
Wells, JC1
Grinshtein, N1
King, JC1
Hao, X1
Dang, NH1
Wang, X1
Aman, A1
Uehling, D1
Datti, A1
Wrana, JL1
Easaw, JC1
Luchman, A1
Weiss, S1
Cairncross, JG1
Kaplan, DR1
Robbins, SM1
Senger, DL1
Belda-Iniesta, C1
Brown, S2
Goktug, T1
Channathodiyil, P2
Hugnot, JP1
Guichet, PO1
Bian, X1
Lee, C1
Hu, K1
Fotovati, A1
Berns, R1
Pambid, M1
Luk, M1
Kong, E1
Toyota, E1
Yip, S1
Toyota, B1
Hothi, P1
Martins, TJ1
Chen, L1
Deleyrolle, L1
Yoon, JG1
Reynolds, B1
Foltz, G1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase II, Multicenter, Open-Label, Single-Arm Study to Evaluate the Safety, Tolerability, and Efficacy of DIsulfiram and Copper Gluconate in Recurrent Glioblastoma[NCT03034135]Phase 223 participants (Actual)Interventional2017-03-09Completed
DIRECT (DIsulfiram REsponse as add-on to ChemoTherapy in Recurrent) Glioblastoma: A Randomized Controlled Trial[NCT02678975]Phase 2/Phase 388 participants (Actual)Interventional2017-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Median Duration of Overall Survival

Duration of overall survival for patients that are alive (NCT03034135)
Timeframe: 14 months

Interventionmonths (Median)
DSF-Cu7.1

Median Progression Free Survival

Duration of progression free survival according to RANO criteria (NCT03034135)
Timeframe: 12 months

Interventionmonths (Median)
DSF-Cu1.7

Number of Participants With Serious Adverse Events

Number of Participants with Grade 3 and 4 serious adverse events (NCT03034135)
Timeframe: 14 months

InterventionParticipants (Count of Participants)
DSF-Cu2

Progression Free Survival

Percentage of patients that are free from progressive disease per RANO criteria (NCT03034135)
Timeframe: 6 months

Interventionpercentage of participants (Number)
DSF-Cu14

Objective Response Rate

ORR will be defined as the percentage of patients with complete response (CR) or partial response (PR) according to the RANO criteria. (NCT03034135)
Timeframe: 6 months

InterventionParticipants (Count of Participants)
Complete responsePartial Response
DSF-Cu00

Overall Survival

Percentage of patients that are alive (NCT03034135)
Timeframe: 6 months and 12 months

Interventionpercentage of participants (Number)
6 months12 months
DSF-Cu6135

Reviews

5 reviews available for disulfiram and Astrocytoma, Grade IV

ArticleYear
Recent advances in the discovery of small molecules targeting glioblastoma.
    European journal of medicinal chemistry, 2019, Feb-15, Volume: 164

    Topics: Animals; Central Nervous System Neoplasms; Drug Discovery; Glioblastoma; Humans; Neoplastic Stem Cel

2019
Clinical, pharmacological, and formulation evaluation of disulfiram in the treatment of glioblastoma - a systematic literature review.
    Expert opinion on drug delivery, 2023, Volume: 20, Issue:4

    Topics: Brain; Brain Neoplasms; Disulfiram; Drug Delivery Systems; Glioblastoma; Humans

2023
A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care.
    Oncotarget, 2013, Volume: 4, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Artemisinins; Auranofin; Brain Neoplasms

2013
Concise review: bullseye: targeting cancer stem cells to improve the treatment of gliomas by repurposing disulfiram.
    Stem cells (Dayton, Ohio), 2015, Volume: 33, Issue:4

    Topics: Animals; Brain Neoplasms; Clinical Trials as Topic; Disulfiram; Drug Delivery Systems; Drug Repositi

2015
Matrix metalloproteinase-2 and -9 in glioblastoma: a trio of old drugs-captopril, disulfiram and nelfinavir-are inhibitors with potential as adjunctive treatments in glioblastoma.
    Archives of medical research, 2012, Volume: 43, Issue:3

    Topics: Angiotensin-Converting Enzyme Inhibitors; Brain Neoplasms; Captopril; Chemotherapy, Adjuvant; Disulf

2012

Trials

4 trials available for disulfiram and Astrocytoma, Grade IV

ArticleYear
Effect of Disulfiram and Copper Plus Chemotherapy vs Chemotherapy Alone on Survival in Patients With Recurrent Glioblastoma: A Randomized Clinical Trial.
    JAMA network open, 2023, 03-01, Volume: 6, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Copper; Disulfiram; Female; Glioblastoma; Humans; Ma

2023
Final results of a phase I dose-escalation, dose-expansion study of adding disulfiram with or without copper to adjuvant temozolomide for newly diagnosed glioblastoma.
    Journal of neuro-oncology, 2018, Volume: 138, Issue:1

    Topics: Adjuvants, Immunologic; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Cohort Studies; Copper;

2018
A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma.
    Journal of neuro-oncology, 2019, Volume: 142, Issue:3

    Topics: Acetaldehyde Dehydrogenase Inhibitors; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplasti

2019
A phase I study to repurpose disulfiram in combination with temozolomide to treat newly diagnosed glioblastoma after chemoradiotherapy.
    Journal of neuro-oncology, 2016, Volume: 128, Issue:2

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Chemoradiotherapy; Dacarbazine; Disulfiram

2016

Other Studies

20 other studies available for disulfiram and Astrocytoma, Grade IV

ArticleYear
Disulfiram Sensitizes a Therapeutic-Resistant Glioblastoma to the TGF-β Receptor Inhibitor.
    International journal of molecular sciences, 2021, Sep-28, Volume: 22, Issue:19

    Topics: Animals; Cell Line, Tumor; Disulfiram; Drug Resistance, Neoplasm; Glioblastoma; Humans; Mice; Mice,

2021
Repurposing Disulfiram for Targeting of Glioblastoma Stem Cells: An In Vitro Study.
    Biomolecules, 2021, 10-21, Volume: 11, Issue:11

    Topics: Disulfiram; Drug Repositioning; Glioblastoma; Temozolomide

2021
PLGA-Nano-Encapsulated Disulfiram Inhibits Hypoxia-Induced NF-κB, Cancer Stem Cells, and Targets Glioblastoma In Vitro and In Vivo.
    Molecular cancer therapeutics, 2022, 08-02, Volume: 21, Issue:8

    Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Disulfiram; Glioblastoma; Humans; Hypoxia; Mice; Neoplas

2022
Nose-to-brain delivery of disulfiram nanoemulsion in situ gel formulation for glioblastoma targeting therapy.
    International journal of pharmaceutics, 2021, Mar-15, Volume: 597

    Topics: Animals; Brain; Cell Line, Tumor; Copper; Disulfiram; Glioblastoma; Nanomedicine; Rats

2021
Blocking distinct interactions between Glioblastoma cells and their tissue microenvironment: A novel multi-targeted therapeutic approach.
    Scientific reports, 2018, 04-03, Volume: 8, Issue:1

    Topics: Acetaldehyde Dehydrogenase Inhibitors; Animals; Anti-Ulcer Agents; Apoptosis; Brain Neoplasms; Carbe

2018
Disulfiram, a Re-positioned Aldehyde Dehydrogenase Inhibitor, Enhances Radiosensitivity of Human Glioblastoma Cells In Vitro.
    Cancer research and treatment, 2019, Volume: 51, Issue:2

    Topics: Acetaldehyde Dehydrogenase Inhibitors; Brain Neoplasms; Caspase 3; Cell Cycle; Cell Line, Tumor; Dis

2019
The efficacy of a coordinated pharmacological blockade in glioblastoma stem cells with nine repurposed drugs using the CUSP9 strategy.
    Journal of cancer research and clinical oncology, 2019, Volume: 145, Issue:6

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Auranofin; Brain Neoplasms; Cap

2019
How could a drug used to treat alcoholism also be effective against glioblastoma?
    Expert review of anticancer therapy, 2013, Volume: 13, Issue:3

    Topics: Alcohol Deterrents; Alcoholism; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Disulfi

2013
Inhibition of NF-κB signaling ablates the invasive phenotype of glioblastoma.
    Molecular cancer research : MCR, 2013, Volume: 11, Issue:12

    Topics: Animals; Cell Line, Tumor; Cell Movement; Disulfiram; Enzyme Inhibitors; Fibronectins; Gene Expressi

2013
CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.
    Oncotarget, 2014, Sep-30, Volume: 5, Issue:18

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Artemisinins; Artesunate; Auran

2014
Development of disulfiram-loaded poly(lactic-co-glycolic acid) wafers for the localised treatment of glioblastoma multiforme: a comparison of manufacturing techniques.
    Journal of pharmaceutical sciences, 2015, Volume: 104, Issue:3

    Topics: Antineoplastic Agents; Brain Neoplasms; Calorimetry, Differential Scanning; Cell Line, Tumor; Cell S

2015
The role of interleukin-18 in glioblastoma pathology implies therapeutic potential of two old drugs-disulfiram and ritonavir.
    Chinese journal of cancer, 2015, Apr-09, Volume: 34, Issue:4

    Topics: Antineoplastic Agents; Dacarbazine; Disulfiram; Glioblastoma; Humans; Interleukin-18; Ritonavir; Tem

2015
Hot melt extruded and injection moulded disulfiram-loaded PLGA millirods for the treatment of glioblastoma multiforme via stereotactic injection.
    International journal of pharmaceutics, 2015, Oct-15, Volume: 494, Issue:1

    Topics: Brain Neoplasms; Cell Line, Tumor; Disulfiram; Drug Carriers; Drug Delivery Systems; Freezing; Gliob

2015
Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, 08-01, Volume: 22, Issue:15

    Topics: Animals; Antineoplastic Agents; Cell Proliferation; Cell Survival; Copper; Dacarbazine; Disease Mode

2016
Suppressing glioblastoma stem cell function by aldehyde dehydrogenase inhibition with chloramphenicol or disulfiram as a new treatment adjunct: an hypothesis.
    Current stem cell research & therapy, 2009, Volume: 4, Issue:4

    Topics: Aldehyde Dehydrogenase; Animals; Brain Neoplasms; Cell Differentiation; Cell Division; Chemotherapy,

2009
Cytotoxic effect of disulfiram/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells.
    British journal of cancer, 2012, Oct-23, Volume: 107, Issue:9

    Topics: Aldehyde Dehydrogenase; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Copper; Cytotoxicity, Immunolo

2012
Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma and over-rides resistance to temozolomide.
    Oncotarget, 2012, Volume: 3, Issue:10

    Topics: Alcohol Deterrents; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms

2012
High-throughput chemical screens identify disulfiram as an inhibitor of human glioblastoma stem cells.
    Oncotarget, 2012, Volume: 3, Issue:10

    Topics: Alcohol Deterrents; Animals; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Proliferation; Disu

2012
Comment on 'cytotoxic effect of disulfiram/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells'.
    British journal of cancer, 2013, Mar-05, Volume: 108, Issue:4

    Topics: Aldehyde Dehydrogenase; Brain Neoplasms; Copper; Disulfiram; Glioblastoma; Humans; Neoplastic Stem C

2013
Reply: Cytotoxic effect of disulfiram/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells.
    British journal of cancer, 2013, Mar-05, Volume: 108, Issue:4

    Topics: Aldehyde Dehydrogenase; Brain Neoplasms; Copper; Disulfiram; Glioblastoma; Humans; Neoplastic Stem C

2013